Table 2.
Characteristics of the 27 included studies
| Characteristics | No (%) of studies |
|---|---|
| Publication year: | |
| 1998-2002 | 1 (4) |
| 2003-07 | 3 (11) |
| 2008-12 | 7 (26) |
| 2013-17 | 16 (59) |
| Geographical region: | |
| Asia | 2 (7) |
| Europe | 5 (19) |
| North America | 9 (33) |
| Multi-continent | 11 (41) |
| Study setting: | |
| Single centre | 3 (11) |
| Multicentre | 20 (74) |
| Not reported | 4 (15) |
| Study design: | |
| Case-control | 1 (4) |
| Non-randomised controlled trial | 1 (4) |
| Cohort | 3 (11) |
| Randomised controlled trial | 22 (81) |
| Study duration (months)*†: | |
| 0-12 | 5 (19) |
| 13-24 | 7 (26) |
| 25-36 | 6 (22) |
| 37-48 | 4 (15) |
| 49-60 | 2 (7) |
| >60 | 2 (7) |
| Not reported | 1 (4) |
| Frequency of interventions examined: | |
| Live attenuated herpes zoster vaccine | 19 (70) |
| Adjuvant recombinant subunit herpes zoster vaccine | 7 (26) |
| Varicella zoster vaccine | 1 (4) |
| Live attenuated herpes zoster vaccine and pneumovax 23 vaccine | 1 (4) |
| Outcomes†‡: | |
| Herpes zoster suspected/confirmed | 22 (81) |
| Herpes zoster ophthalmicus | 3 (11) |
| Post-herpetic neuralgia | 4 (15) |
| Injection site adverse event | 21 (78) |
| Systemic adverse event | 17 (63) |
| Serious adverse event | 20 (74) |
| Withdrawals related to adverse event | 17 (63) |
| Potential immune mediated disease | 4 (15) |
| Death | 20 (74) |
| Quality of life | 0 (0) |
*
Mean 30.9 (SD 22.3) months.
†
Also, see Appendix S1 for definitions.
‡
Not all studies could be included in pooled analysis.